BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

7 years ago
News Briefing

Work with Flori­da on its drug im­port pro­gram, Trump tells Azar — re­port

7 years ago
Pharma

Look­ing to top­ple Pfiz­er's Pre­vnar 13 dy­nasty, Mer­ck claims an­oth­er win for its 'break­through' pneu­mo­coc­cal con­ju­gate ...

7 years ago
R&D

Sarep­ta goes back to the gene ther­a­py well at Na­tion­wide Chil­dren’s for its lat­est mus­cle-wast­ing pro­gram

7 years ago
Cell/Gene Tx

Till­man Gern­gross is­n't out to im­press you with biobucks, but here are 3 part­ner deals that should

7 years ago
People
Pharma

Pfiz­er buys a rare dis­ease biotech for $340M-plus, putting them on a path to com­pete with Bio­Marin

7 years ago
R&D
Pharma

Gilead wa­gers $109M — cash — that this biotech can il­lu­mi­nate a drug dis­cov­ery path point­ed straight in­to the ...

7 years ago
R&D

As­traZeneca’s $7B bet on Dai­ichi Sankyo’s an­ti­body drug con­ju­gate pays off with piv­otal da­ta to back their ...

7 years ago
R&D

Re­gen­eron’s star bis­pe­cif­ic is linked to 2 deaths in a small study — which was no help for its Q1 call

7 years ago
R&D

Brent Saun­ders has a mes­sage for Al­ler­gan in­vestors to­day: He feels your pain

7 years ago
People

Bel­gium's liv­er-fo­cused stem cell ther­a­py de­vel­op­er Promethera rais­es $44M+ in lat­est round

7 years ago
Financing

Con­fo Ther­a­peu­tics rais­es €30 mil­lion; Waylivra re­ceives ap­proval from EU; end­point met for Mer­ck­'s Bel­som­ra in ...

7 years ago
News Briefing

$250M As­traZeneca spin­off preps leap in­to 3-way bat­tle with ti­tans for a rare dis­ease mar­ket that spans the globe

7 years ago
R&D

Rat­tle and hum: Roche, PTC post up­date on their SMA drug as a shak­en Bio­gen faces yet an­oth­er fran­chise buster

7 years ago
R&D
Pharma

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

7 years ago
People
R&D

Catch­ing Cat­a­lyst Phar­ma by sur­prise, FDA ap­proves Ja­cobus LEMS drug for pe­di­atric pa­tients — based on adult da­ta

7 years ago
R&D
Pharma

Watch out Ab­b­Vie and J&J, As­traZeneca just took an­oth­er big swing at one of your star can­cer drug fran­chis­es

7 years ago
R&D
Pharma

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

7 years ago
People
R&D

One of the world's top ex­perts in coro­nary heart dis­ease is spear­head­ing a new gene edit­ing up­start out to trans­form ...

7 years ago
People
Startups

GW Phar­ma scores an­oth­er PhI­II win for its cannabi­noid in rare form of epilep­sy

7 years ago
R&D

Es­pe­ri­on shares surge as FDA waves off pan­el re­view; Adap­ti­m­mune buoyed by a pos­i­tive da­ta snap­shot

7 years ago
News Briefing

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

7 years ago
People

Bill Haney's Sky­hawk spears an­oth­er mar­quee al­liance for its work drug­ging RNA in Take­da neu­ro pact

7 years ago
People
R&D

Pfiz­er en­ters Al­ny­lam, Ion­is' TTR turf with ear­ly ap­proval for car­diomy­opa­thy drug, car­ry­ing a $225K price tag

7 years ago
R&D
Pharma
First page Previous page 936937938939940941942 Next page Last page
A service from the Financial Times